

Level 14, Cigna House,
40 Mercer Street, PO Box 10-254
Wellington 6001, New Zealand
Phone 64 4 460 4990
Fax 64 4 460 4995
www.pharmac.govt.nz

22 September 2004

To: All Pharmaceutical Suppliers, Medical Groups and Interested Parties

CONSULTATION ON REFERENCE PRICING OF TERBINAFINE TABLETS 250 mg

PHARMAC proposes to reference price all brands of terbinafine 250 mg tablets listed on the Pharmaceutical Schedule, with effect from 1 December 2004. The new subsidy of \$53.57 per 30 (ex-manufacturer, exc. GST) would apply as follows:

Chemical and presentation	Brand	Pack size	Current subsidy	Proposed subsidy
Terbinafine 250 mg tablets	Lamisil	14	\$58.10	\$25.00
	Terbafin	30	\$53.57	\$53.57

This proposal will be considered by the PHARMAC Board or by the Chief Executive under Delegated Authority in October 2004. If you have comments to make on this proposal and would like those comments to be considered by the PHARMAC Board or the Chief Executive then please send them to Deepti Chotai at PHARMAC **by 5 p.m. on 7 October 2004**. The Board will consider all comments submitted by this date.

Yours sincerely



Deepti Chotai
Therapeutic Group Manager